Endoglin Antikörper

Produktnummer ABIN1981863

Produktdetails anti-Endoglin Antikörper

Target: Endoglin (ENG)

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser Endoglin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: The rat monoclonal antibody MJ7/18 reacts with an extracellular epitope of CD105 (Endoglin), a 90 kDa type I homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow.

Kreuzreaktivität (Details): Mouse

Aufreinigung: Purified by protein-G affinity chromatography.

Reinheit: > 95 % (by SDS-PAGE)

Immunogen: Inflamed mouse skin

Klon: MJ7-18

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Recommended dilution: 1-4 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze. Do not use after expiration date stamped on vial label.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Do not freeze.

Referenzen für anti-Endoglin Antikörper (ABIN1981863)

Dassler, Roohi, Lohrke, Ide, Remmele, Hütter, Pietsch, Pison, Schütz: "Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles." in: Investigative radiology, Vol. 47, Issue 7, pp. 383-91, (2012) (PubMed).

Rosu-Myles, She, Fair, Muradia, Mehic, Menendez, Prasad, Cyr: "Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells." in: PLoS ONE, Vol. 7, Issue 6, pp. e38954, (2012) (PubMed).

Fonsatti, Nicolay, Altomonte, Covre, Maio: "Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours." in: Cardiovascular research, Vol. 86, Issue 1, pp. 12-9, (2010) (PubMed).

Warrington, Hillarby, Li, Letarte, Kumar: "Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells." in: Anticancer research, Vol. 25, Issue 3B, pp. 1851-64, (2005) (PubMed).

Herouet, Cottin, LeClaire, Enk, Rousset: "Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells." in: In vitro & molecular toxicology, Vol. 13, Issue 2, pp. 113-23, (2001) (PubMed).

Details zu Endoglin

Target: Endoglin (ENG)

Andere Bezeichnung: CD105 (ENG Produkte)

Synonyme: ENG antikoerper, MGC137842 antikoerper, DKFZp469D0419 antikoerper, END antikoerper, HHT1 antikoerper, ORW1 antikoerper, AI528660 antikoerper, AI662476 antikoerper, CD105 antikoerper, S-endoglin antikoerper, endoglin antikoerper, ENG antikoerper, Eng antikoerper

Hintergrund: Endoglin,CD105 (endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.,Endoglin, END, ENG

Gen-ID: 13805

UniProt: Q63961